Scientific Discovery

“Somewhere, something incredible is waiting to be known.”

— Carl Sagan

Consider the list of the most valuable companies in the United States, and then consider what that list looked like forty years ago. Most of today’s giants were small, or private, or did not exist. The industries that now dominate, in software, in mobile computing, in advanced medicine and artificial intelligence, were science projects or science fiction. The market did not stay the same and reward you for loyalty. It refreshed itself, again and again, as discovery turned into new products, new companies, and new ways of living. That churn is not a bug in the system. It is the system.

For an investor, scientific discovery is the reason the long-term story keeps renewing rather than running out. A static economy would eventually exhaust its opportunities. An economy that keeps inventing does not. The polio vaccine, the transistor, the microprocessor, the internet, the mapping of the human genome, the mRNA platform that produced COVID vaccines in under a year, these were not just humanitarian milestones. Each one created industries, productivity, and wealth that did not exist before, and a great deal of that wealth flowed to the people who owned the businesses built on top of it.

Why you do not have to pick the winner

The natural temptation when reading about innovation is to try to identify the next breakthrough and bet on it. Resist it. Picking which specific technology, let alone which specific company, will win is extraordinarily hard, and the history of investing is littered with people who were right about the technology and wrong about the stock. Many of the most transformative inventions made their pioneers very little money and their imitators a fortune.

The good news is that you do not need to guess. The whole point of owning a broad, diversified slice of the market is that you own the future winners automatically, without having to name them in advance. When a new industry rises, it rises inside your index. When today’s leaders are displaced by tomorrow’s, the index quietly swaps them out and you keep owning the productive frontier. Scientific discovery is what makes that frontier worth owning. Diversification is what lets you own it without the impossible task of forecasting which discovery pays off.

This is also the calm answer to the anxiety about artificial intelligence. No one can tell you with confidence which companies will capture the value AI creates, or how the competition will shake out. You do not have to know. If AI proves as economically important as its advocates believe, a broadly diversified, long-term investor will participate in that value as it accrues to whichever businesses ultimately earn it. The forecast is unnecessary. The ownership is sufficient.

Why the American advantage is hard to copy

It is worth being specific about why so much discovery still happens here, because these are structural advantages a competitor cannot simply decide to buy. They took generations to build, and they reinforce one another.

Start with the universities and research labs. The United States is home to a deep bench of world-leading research institutions, public and private, and to corporate research laboratories whose annual budgets run into the tens of billions of dollars, more than many nations spend on research altogether. That concentration of talent and funding is difficult to assemble and harder to sustain.

Add the legal foundations described elsewhere in this series. Strong protection for intellectual property means an inventor can expect to own what they create, and the rule of law means a patent or a contract will be honored. An idea is only worth chasing if the person who has it can capture the reward, and American law makes that a reasonable expectation. It is a large part of why inventors and capital from around the world keep coming here.

But the advantage that may matter most is the least appreciated: how the United States finances new ideas. In much of the world, a young company is funded by a bank, and a banker reasonably wants to see years of profit before committing a dollar. That is prudent, and it is also fatal to the kind of venture that has no results yet, only a gifted team and an idea. The American system runs differently. Venture capital and private equity investors will put serious money behind exactly that, a few talented scientists and a promising concept, knowing most such bets will fail and that the rare success will pay for all the rest. Many of the firms now leading in software, biotechnology, and artificial intelligence were funded when they had little more than that. A financing culture willing to take that risk is not easily copied, and it is one of the deepest reasons new industries are so often born here.

Concerns

American science is not without real concerns. Federal research spending as a share of the economy is well below its mid-century peak, even as global competitors, China most prominently, have increased theirs sharply and now rival or exceed the United States on some measures of research output. Funding can be volatile and politically buffeted. Critics worry that the grant system rewards safe, incremental work over the bold, uncertain projects that produce genuine breakthroughs. These are legitimate worries, and they are worth watching.

But none of this undoes the advantages just described. The country continues to produce a disproportionate share of the world’s patents, Nobel laureates, and foundational breakthroughs. Competition from abroad is a reason for vigilance, not despair. More science being done in more places, on balance, means more discovery, and a diversified investor owns businesses around the world.

What it means for you

Scientific discovery is the pillar that keeps the others from going stale. It is why the long arc is not just a story about the past but a reasonable expectation for the future, because the engine that produced the gains is still running and still accelerating in many fields.

Your job is not to predict the next breakthrough. It is to own the productive economy broadly enough that, whatever the next breakthrough turns out to be, and whoever ends up profiting from it, you are already an owner.

Sources

National Science Foundation, R&D spending data. Patent counts from the U.S. Patent and Trademark Office; Nobel laureate counts from the Nobel Foundation.

Important Disclosures